In this webinar we hear from Professor Guy Ludbrook, Director of PARC Clinical Research, at the Royal Adelaide Hospital and Dr. Gabriel Kremmidiotis, Chief Scientific Officer at Avance Clinical, on how to navigate drug development, strategy and regulatory policy in planning early phase trials in Australia.
Professor Ludbrook has been involved in numerous investigator-initiated and industry sponsored clinical trials, as a Principal Investigator, Consultant, Monitor, and Data Safety Board member and has significant breadth and depth of knowledge and experience in clinical research.
Hear first-hand about the importance of planning with the end goal in mind while engaging and investing in subject matter expertise as early as possible in program drug development planning. The webinar will also cover:
PhD, BSC Hon
Chief Scientific Officer
Gabriel has 26 years’ experience in medical research and drug development. He has devoted most of his career to the biotechnology industry, managing drug development programs from early discovery to completion of phase II proof of concept clinical trials and subsequent commercial drug licensing deals.
He has been part of the CPR Pharma Services team since 2015 managing the department of clinical operations and offering drug development advice to biotechnology companies seeking to enter clinical trials in Australia. In 2019, Gabriel was appointed Chief Scientific Officer of Avance Clinical where he currently leads the Department of Scientific and Medical affairs offering Medical Writing, Drug safety monitoring and reporting and early phase clinical drug development and regulatory advice services.
Prior to joining CPR Pharma Services, Gabriel was the Vice President Research & Development of the Australian ASX listed company Bionomics limited where over several years led teams in discovery and progression of cancer therapeutics through to completion of several phase I and Phase II clinical trials in Australia and the US.
Gabriel’s 26 years in medical research also includes appointments with the Cancer Therapeutics CRC, Flinders University of South Australia, Adelaide University, the Los Alamos National Laboratories and the Adelaide Women’s and Children’s Hospital.
With primary expertise in oncology, Gabriel has a diverse scientific background spanning the fields of Clinical Development, Drug Discovery, Cancer Biology, Molecular Genetics, Bioinformatics and Immunology. He has a PhD and a Bachelor of Science (Honours) from Flinders University and a Bachelor of Science from The University of Melbourne. He has published research findings in 29 international scientific papers and has several patent inventions on cancer genes and small molecule anti-cancer therapeutics. Gabriel is a member of the American Association for Cancer Research, the American Society of Clinical Oncology and ARCS Australia.
Professor of Anaesthesia
Royal Adelaide Hospital
Guy Ludbrook is Professor of Anaesthesia at the Royal Adelaide Hospital, Head of Acute Care Medicine at the University of Adelaide and is the Director of an early phase clinical trials unit, PARC Clinical Research. His original research background is in pharmacology, particularly related to pharmacokinetics and pharmacodynamics in the CNS. After spending some time at London Business School, he has developed an interest in innovation in health services delivery, especially related to the value proposition of both outcome and cost. He is active in research into improved evidence-based models of care preoperatively and post-operatively.
He is involved in numerous investigator-initiated and industry clinical trials, as a Principal Investigator, Consultant, Monitor, and Data Safety Board member.
He has substantial experience in regulation through Committees of the Therapeutic Goods Administration.
He is currently studying Health Economics at London School of Economics with a specific focus on quality and cost-effectiveness of both health systems and therapeutic goods.
Business Development Associate